Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease

Strebel, Bruno M; Dufour, Jean-François (2008). Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert review of anticancer therapy, 8(11), pp. 1743-9. London: Expert Reviews 10.1586/14737140.8-11.1743

Full text not available from this repository. (Request a copy)

Depending on tumor burden, hepatic function and patients' performance status, hepatocellular carcinoma is treated by surgery, local procedures, systemic therapy or palliation. The majority of patients are diagnosed at a stage where local therapy is the treatment of choice. Recently, the multikinase inhibitor sorafenib was found to improve the survival of patients with advanced hepatocellular carcinoma and conserved liver function. In this manuscript, we summarize the experimental evidence supporting the combination of a systemic targeted therapy with a local therapy. We also discuss the pros and cons of different schedules of combining such treatments. We conclude that there is enough of a theoretical argument to design clinical trials testing this strategy.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology 04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology
UniBE Contributor:	Strebel, Bruno Michael, Dufour, Jean-François
ISSN:	1473-7140
ISBN:	18983234
Publisher:	Expert Reviews
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 15:05
Last Modified:	05 Dec 2022 14:20
Publisher DOI:	10.1586/14737140.8-11.1743
PubMed ID:	18983234
Web of Science ID:	000261050100004
URI:	https://boris.unibe.ch/id/eprint/28358 (FactScience: 120272)